TARA Stock Forecast: Protara Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.28
−5.00% on the day

The median 12-month analyst price target for Protara Therapeutics, Inc. is $26. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$147.8M
Ticker Nerd rank
26/ 100
Median analyst target
$26
Analysts covering
8
Revenue$0.0
Operating income−$23.3M
Net income−$21.7M
Free cash flow−$15.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
−10.9%
YTD
−57.2%
1Y
−64.6%
From 52W high
−69.8%
From 52W low
+7.0%
$2.13
$7.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Protara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
26/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
60
Quality
55
Revisions
44
Accruals
41
Value
37
Issuance
36
Growth
21
Momentum
17

Volatility (60): The share price has been relatively steady.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TARA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TARA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Jan 26Apr 26Jul 26Oct 26TARAHigh $30Median $26Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$18
Low
$26
Median
$30
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026OppenheimerMaintainsOutperform$25 → $28
14 May 2026JP MorganMaintainsOverweight$27 → $26
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
4 Mar 2026JP MorganInitiatesOverweight—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026Piper SandlerInitiatesOverweight—
3 Dec 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
22 May 2025Jones TradingInitiatesBuy—
28 Apr 2025HC Wainwright & Co.ReiteratesBuy—
16 Apr 2025ScotiabankInitiatesSector Outperform—
14 Mar 2025Cantor FitzgeraldInitiatesOverweight—
11 Mar 2025LifeSci CapitalInitiatesOutperform—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
6 Dec 2024GuggenheimReiteratesBuy—
6 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024OppenheimerMaintainsOutperform—
8 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TARA.

Market Radar

This page is one stock. Monday covers all of them.

TARA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TARA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Protara Therapeutics, Inc. returned −64.6% against +6.9% for the S&P 500, dividends included.

TARA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TARAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TARA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.0×

Cheaper than 70% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−57.4%

Higher than 20% of US stocks

Return on assets
−35.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Protara Therapeutics, Inc. has a market value of $147.8M and an enterprise value of $23.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$70.0M.

  • Diluted earnings per share, trailing twelve months: −$1.35.

  • Free cash flow in the twelve months to 30 June 2026: −$66.5M.

  • Shares outstanding: 59.1M.

  • Protara Therapeutics, Inc. employs 46 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TARA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TARAProtara Therapeutics, Inc.$147.8M26
ALXOALX Oncology Holdings, Inc.$137.0M44
ABEOAbeona Therapeutics, Inc.$138.1M53
STROSutro Biopharma, Inc.$140.9M56
ZNTLZentalis Pharmaceuticals, Inc.$128.8M44
SIONSionna Therapeutics, Inc.$126.1M21
ELDNEledon Pharmaceuticals, Inc.$144.6M29

Take a look at TARA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Protara Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TARA

What is the TARA stock price forecast for 2026-2027?

The median 12-month analyst price target for Protara Therapeutics, Inc. is $26, with estimates ranging from $18 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TARA stock a buy right now?

Of the 8 analysts covering Protara Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protara Therapeutics, Inc. 26 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TARA?

As at 21 Nov 2026, Protara Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (60 of 100).

Will TARA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $26, and Ticker Nerd's factor model ranks Protara Therapeutics, Inc. 26 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TARA stock forecast for 2030?

No analyst covering Protara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $30 over the next 12 months.

How has TARA stock performed over the past year?

Protara Therapeutics, Inc. returned -64.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Protara Therapeutics, Inc. do?

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition.

Company

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition. The company’s programs address areas with significant unmet medical need across oncology, rare disease, gastrointestinal, and metabolic care. Protara Therapeutics operates as a research-driven developer of specialty treatments, with its portfolio aimed at advancing targeted options for patient populations that have limited approved alternatives. Headquartered in New York, New York, the company focuses on clinical development and translational science to support its therapeutic candidates.

CEO Mr. Jesse Shefferman · 46 employees · United States · https://www.protaratx.com